Introduction
============

A fixed-dose combination of metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor has been shown to be an effective and particularly safe and convenient treatment strategy.[@b1-vhrm-9-711],[@b2-vhrm-9-711] In patients who do not reach their individual target glycosylated hemoglobin (HbA~1c~) or fasting plasma glucose levels using this combination, adding a long-acting insulin (analog) is an attractive option for treatment escalation because of the combination of complementary effects of long-acting insulin and incretin-based therapies on fasting and postprandial glucose and consequently HbA~1c~[@b3-vhrm-9-711]--[@b5-vhrm-9-711]

A recent study by Arnolds et al[@b6-vhrm-9-711] performed in 48 subjects investigated whether addition of sitagliptin 100 mg/day to an existing treatment of insulin glargine titrated to achieve fasting plasma glucose ≤100 mg/dL and/or metformin results in improved blood glucose control. Reduced 6-hour postprandial glucose excursions were found (612±133 mg/dL per hour with the triple combination versus 728±132 mg/dL per hour with insulin glargine/metformin, *P*=0.0008). The triple combination was safe, and hypoglycemia rates (no major hypoglycemia) were generally low and comparable between the groups. Hollander et al[@b3-vhrm-9-711] evaluated the efficacy and safety of insulin detemir added to an existing treatment with metformin/sitagliptin compared with metformin/sitagliptin with or without sulfonylurea. Reductions in HbA~1c~ (−1.44% versus −0.89%, *P*\<0.001) and fasting plasma glucose (−3.7 versus −1.2 mmol/L, *P*\<0.001) were larger in the insulin detemir group, with no differences in weight changes and no episodes of major hypoglycemia.

These reports prompted us to investigate whether the results of these studies could be reproduced in a clinical practice setting where patients do not necessarily match those of randomized controlled trials.[@b7-vhrm-9-711] For treatment escalation, we used insulin glargine, a long-acting insulin analog, as a proven flexible and efficient therapeutic option[@b8-vhrm-9-711],[@b9-vhrm-9-711] with a low risk of hypoglycemia.[@b10-vhrm-9-711] We added insulin glargine to a treatment regimen of metformin and a DPP-4 inhibitor established for at least 3 months in patients with an HbA~1c~ that remained elevated (7.5%--10%). This observational study had two principal objectives: to document glycemic efficacy (HbA~1c~), fasting plasma glucose, and insulin glargine doses used between baseline and the end of 20 weeks of follow-up; and to investigate the safety and tolerability of initiating insulin glargine in these patients.

Materials and methods
=====================

GOLD (Blood glucose reGulatiOn with Lantus® and a DPP-4 inhibitor in basal supported oral therapy \[BOT\] in type 2 diabetes patients) was a noninterventional, noncontrolled multicenter, prospective observational study. The study was carried out in accordance with §67(6) of the German Medicines Law (Arzneimittelgesetz, AMG), which does not allow stipulation of particular treatments or procedures, but monitoring of treatment decisions. It was announced to the Federal Institute of Drugs and Medical Devices (BfArM), the German Medical Association (Kassenärztliche Bundesvereinigung), and the head organizations of health insurance funds as necessary. The protocol of the study was approved by the ethics committee of the Berlin Chamber of Physicians on November 3, 2010. Patients had to provide written informed consent prior to enrolment.

Patients
--------

Patients with type 2 diabetes mellitus were included in this observational trial, provided that they were at least 18 years old, had an HbA~1c~ between 7.5% and 10%, had taken a combination of metformin and any DPP-4 inhibitor (agents used not specified) for at least 3 months previously, were insulin-naïve, and were able to perform blood glucose self-measurements. Patients were only considered for inclusion if the treating physician had made a decision to use insulin glargine at baseline. Patients were excluded if they had received prior treatment with insulin, sulfonylureas, thiazolidinediones (glitazones), glucagon-like peptide-1 receptor agonists or acarbose within the previous 6 months, had experienced episodes of severe hypoglycemia during the course of the disease (blood glucose \<56 mg/dL or \<3.1 mmol/L), or had a history of alcohol or drug abuse, or dementia, or a general inability to comply with the study requirements. Further, patients with a contraindication to insulin glargine were excluded. On the other hand, we did not stipulate specific contraindications for metformin or DPP-4 inhibitors.

Outcome measures
----------------

The principal outcome measures for the study were mean changes in HbA~1c~, and the proportion of patients reaching an HbA~1c~ \<6.5% or \<7.0% from the start of treatment with insulin glargine to the end of the 20-week observation period. Further, changes in fasting plasma glucose and the proportion of patients achieving a fasting plasma glucose \<100 mg/dL (5.6 mmol/L) were analyzed.

Secondary outcome measures were: achievement of individualized treatment goals for fasting plasma glucose; mean change in insulin dose per day and number of adjustments; mean change in numbers of daily insulin injections; changes in timing of administration of insulin; mean change in metformin dose; mean change in body weight; use of blood glucose test strips; and consumption of pen needles per day and per month at endpoint. The specific DPP-4 inhibitor and its dose were not recorded.

Safety parameters were: incidence of confirmed symptomatic hypoglycemia with blood glucose levels ≤70 mg/dL (3.9 mmol/L); incidence of confirmed severe hypoglycemia with blood glucose levels \<56 mg/dL (3.1 mmol/L); and the incidence of other spontaneously reported adverse events, such as dizziness, erysipelas, hyperhidrosis, weight gain, and convulsions, classified by severity.

Statistics
----------

Power calculations showed that about 1,600 patients were needed to be able to answer the predefined primary research questions. This number was calculated based on the assumption of a normally distributed HbA~1c~ decrease of 0.4%±1.2%, with a 95% confidence interval (CI) ranging from 0.341% to 0.459%. A normally distributed fasting plasma glucose decrease of 20±60 mg/dL would have a 95% CI ranging from 17.06 mg/dL to 22.94 mg/dL. An observed response rate of 25%, 50%, and 75% would result in 95% CIs of 22.9%--27.1%, 48.1%--51.9%, and 72.9%--77.1%, respectively. Adverse events occurring in one of 534 patients were determined to be observable with a probability of 95% and those occurring in one of 1,000 patients (eg, hypoglycemia) with a probability of 80%.

Double data entry was done using DMSys® version 5.1 (Sigmasoft International, Naples, FL, USA). A comparison with the source documentation was performed at 21 sites (3.23% of all sites). All patients documented were regarded as the safety set, and all patients complying with the selection criteria as the efficacy set. Because selected variables were missing in some patients, we considered only the subsets with available data, as indicated in the tables for calculating proportions. Statistical analysis of all collected data was performed using descriptive measures according to a predefined statistical analysis plan. Continuous data were described by the mean ± standard deviation. Categorical data were described using absolute and relative frequencies. The 95% CIs were reported for the mean changes in HbA~1c~, fasting plasma glucose, and for other estimated parameters. Data were evaluated using Statistical Package for the Social Sciences version 15 software (SPSS Inc., Chicago, IL, USA).

Results
=======

A total of 1,483 patients were documented by 650 office-based physicians (66.5% general practitioners, 33.0% internists, and 0.5% of both professions, with 2.3±1.5 patients per center) across Germany on the basis of a representative demographic pattern between January 1, 2010 and January 9, 2012. These patients were considered the safety set. Among these, no prior metformin/DPP-4 inhibitor treatment was recorded in 170 patients, and a further 51 patients were treated with insulin despite not complying with some of the other selection criteria. This resulted in 1,262 patients being available for the efficacy analysis. [Table 1](#t1-vhrm-9-711){ref-type="table"} shows the baseline characteristics for these 1,262 patients, who comprised a typical patient population with type 2 diabetes mellitus with respect to age and sex distribution, presence of comorbidities, and blood glucose control. Insulin glargine was initiated on average, 1.1±11.2 days prior to the baseline evaluation at a mean dose of 13.35±7.04 units per day.

Mean changes and achievement of target HbA~1c~ and fasting plasma glucose
-------------------------------------------------------------------------

Mean HbA~1c~ decreased from 8.51% to 7.36%, corresponding to a mean change of −1.15%±0.91% (95% CI −1.20 −1.10, [Table 2](#t2-vhrm-9-711){ref-type="table"}). An HbA1 level \<6.5% was achieved in 8.2% of patients and a level \<7.0% in 31.5%. The mean fasting plasma glucose (n=1,197) decreased from 174±47 mg/dL to 127±31 mg/dL, corresponding to a mean change of −47.3±44.1 mg/dL (95% CI −49.8 to −44.8). A fasting plasma glucose level \<100 mg/dL was achieved in 11.9% of patients. Individualized fasting plasma glucose goals were achieved in 35.9%. This was because actual treatment goals for fasting plasma glucose were slightly higher than 100 mg/dL (mean fasting plasma glucose goal 117.5±14.0 mg/dL; 78.2% between 100 and \<130 mg/dL, [Table 3](#t3-vhrm-9-711){ref-type="table"}).

Secondary outcomes
------------------

During the approximately 20 weeks of treatment, the dose of insulin glargine was initiated at 13.43±7.11 units/day and then increased to 20.39±9.54 units/day at the end of follow-up, corresponding to a mean change of 6.96±7.70 units/day on treatment ([Table 3](#t3-vhrm-9-711){ref-type="table"}). The frequency of insulin dose adjustments decreased during the observation period. In the first month, a mean of 1.35±1.24 insulin adjustments took place, with a decrease in months 2 (1.04±0.93), 3 (0.72±0.87), 4 (0.52±0.79), and 5 (0.39±0.75).

Insulin glargine was injected in the majority of patients once a day post baseline (96.59%) and after 20 weeks of observation (90.33%). Only 1.82% and 2.93% of the patients, respectively, injected insulin glargine twice daily. Preferred administration times were at bedtime (42.63% post baseline and 40.10% after 20 weeks) and in the evening (36.69% and 34.31%, respectively, [Table 3](#t3-vhrm-9-711){ref-type="table"}).

Safety
------

A total of 29 adverse events occurred in 13 patients (0.88%, [Table 4](#t4-vhrm-9-711){ref-type="table"}). Relevant adverse events were hypoglycemia (0.20%) and dizziness, erysipelas, hyperhidrosis, and weight increase (0.13% each). Serious adverse events were observed for 0.40% (n=6) of patients. In two patients with a total of five events, a causal relationship with insulin glargine could not be excluded. Reported adverse drug reactions were hypoglycemia (0.13%), convulsions, hyperhidrosis, and weight increase (0.07% each). Serious adverse drug reactions were observed in one patient (hypoglycemia and convulsions, 0.07%). One patient died during the study for reasons unrelated to insulin glargine treatment. Hypoglycemia (blood glucose ≤70 mg/dL) was observed in 29 patients (2.30%), of whom six (0.48%) occurred during the night and four (0.32%) were considered to be severe (blood glucose \<56 mg/dL). The mean number of confirmed hypoglycemic episodes was 1.88±1.03 (n=24).

Treatment satisfaction
----------------------

At the end of the 20-week observation period, 92.6% of patients were continuing their insulin glargine treatment (no data available for 4.2%). Physicians indicated that the main reason for discontinuation of insulin glargine was insufficient blood glucose control (n=17, 1.35%). One patient discontinued because of adverse events. For the other patients (n=15), no reason for discontinuation was recorded.

Discussion
==========

The role of insulin in the treatment of patients with type 2 diabetes has evolved considerably within the last decade from being a last resort treatment to a first-line drug that may be used at any stage of the disease. Early treatment with insulin is thought to protect the beta-cell from the consequences of long-term exposure to hyperglycemia.[@b11-vhrm-9-711] Early initiation, as suggested by the recent results of the ORIGIN (Outcome Reduction with an Initial Glargine Intervention) trial,[@b12-vhrm-9-711] is powerful in improving long-term glycemic control, and may prevent or delay chronic complications in patients with type 2 diabetes.[@b13-vhrm-9-711]--[@b16-vhrm-9-711] In real-world clinical practice however, timely initiation of insulin is often hampered by concerns about weight gain, hypoglycemia, and the patient's fear of injections.[@b17-vhrm-9-711]

The aim of this noninterventional study in clinical practice was to observe and analyze the use of insulin glargine added to a baseline combination treatment of metformin and a DPP-4 inhibitor in patients with type 2 diabetes mellitus. We found an HbA~1c~ reduction of 1.15% and a decrease in fasting plasma glucose of 47.25 mg/dL, with a low frequency of hypoglycemic episodes (2.30% any and 0.32% severe) over a treatment duration of 20 weeks. Body weight did not increase; on the contrary, it was reduced by about 1 kg. Adverse drug reactions were recorded in two patients (0.13%) and serious adverse drug reactions in one patient. Treatment satisfaction was high, with at least 92.6% of patients continuing their treatment beyond the observation period.

These results are in agreement with previous randomized controlled trial results suggesting that the complementary action of long-acting insulin and incretin-based treatment strategies on a background metformin therapy is both effective and well tolerated, in that it is associated with a low rate of hypoglycemia and comes without weight gain.[@b3-vhrm-9-711]--[@b6-vhrm-9-711] In a previous randomized controlled trial,[@b3-vhrm-9-711] when insulin detemir was added to a combination of sitagliptin and metformin versus a combination of sitagliptin, metformin, and a sulfonylurea, a mean HbA~1c~ decrease of 1.44% was observed within 26 weeks, and fasting plasma glucose decreased by 66.3 mg/dL (3.7 mmol/L) when basal insulin was added. Small decreases were seen in body weight and body mass index. Rates of hypoglycemia were low (1.3 episodes per year), with no severe episodes recorded.

Insulin is frequently used when HbA~1c~ values rise above 7.5% or 8.0% despite multiple combinations of oral antidiabetic drugs. This is in contrast with a recent study in patients with type 2 diabetes who were inadequately controlled by metformin, in whom the early use of basal insulin was associated with a significant improvement in residual pancreatic beta-cell function.[@b18-vhrm-9-711] In the EARLY (Early Basal Insulin Therapy under Real-Life Conditions in Type 2 Diabetics)[@b19-vhrm-9-711] observational trial, the use of basal insulin glargine in patients on maximal doses of metformin reduced HbA~1c~ from 8.7% to 7.4% within 24 weeks, with a low risk of hypoglycemia and slightly decreased weight. Multivariate analysis demonstrated better results in patients with a shorter history of diabetes and a higher HbA~1c~ at baseline.[@b19-vhrm-9-711],[@b20-vhrm-9-711] Fonseca et al confirmed these results in a recent meta-analysis demonstrating the benefits of early addition of basal insulin to metformin compared with a prior combination of metformin and a sulfonylurea.[@b21-vhrm-9-711] Patients on metformin monotherapy and add-on insulin glargine achieved a greater reduction in HbA~1c~, with lower rates of severe hypoglycemia and less weight gain compared with those on metformin plus sulfonylurea at baseline.

The design of this study, documenting real world clinical practice, has some inherent limitations. An important aspect to be considered is its nonrandomized and noncontrolled design. This may have led to a selection bias towards patients in whom a low rate of complications may be expected. Further, treatment effects and complications such as hypoglycemia cannot be linked to a particular treatment. Because of the lack of a control group taking placebo or an active substance such as a sulfonylurea, the impact of a closer surveillance within this observation cannot be quantified. Another aspect is the rather poor control at baseline with a mean HbA~1c~ of 8.5% and fasting plasma glucose of 174 mg/dL (9.7 mmol/L), which is similar to the study reported by Hollander et al.[@b3-vhrm-9-711] Because of the high HbA~1c~ at baseline, the relative contribution of fasting plasma glucose versus postprandial plasma glucose to HbA~1c~ may be increased,[@b22-vhrm-9-711] favoring the action of insulin.

Conclusion
==========

The results of this observational study showed that insulin glargine, when added to a combination of metformin and a DPP-4 inhibitor, resulted in a significant and clinically relevant improvement of glycemic control. This intervention did not interfere with the drug profile of the DPP-4 inhibitors, resulting in neutral effects on weight and low rates of hypoglycemia. This approach was shown to be useful, effective, and safe in daily clinical practice when treatment has to be intensified in patients who are not well controlled on oral antidiabetic drugs. These results may further help to promote the timeliness of establishing insulin therapy in these patients.
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###### 

Patient demographics (n=1,262)

                                                                            n available   Mean ± SD or n (%)
  ------------------------------------------------------------------------- ------------- --------------------
  Age (years)                                                               1,262         64.2±10.7
  Female sex                                                                1,258         562 (44.7)
  Body weight (kg)                                                          1,227         89.6±16.8
  Body mass index (kg/m^2^)                                                 1,260         30.76±5.05
  Diabetes duration ≥5 years                                                1,255         905 (72.1)
  Blood glucose values                                                                    
   HbA~1c~ (%)                                                              1,247         8.50±0.98
   Fasting blood glucose (mg/dL)                                            1,242         174.0±46.6
  Diabetes-related comorbidity[\*](#tfn1-vhrm-9-711){ref-type="table-fn"}                 
   None                                                                     1,255         436 (34.7)
   Microalbuminuria                                                         1,225         402 (32.8)
   Macroalbuminuria                                                         1,215         57 (4.7)
   Nephropathy                                                              1,222         175 (14.3)
   Retinopathy                                                              1,217         175 (14.3)
   Neuropathy                                                               1,230         381 (31.0)
   Diabetic foot syndrome                                                   1,225         108 (8.8)
   Coronary artery disease                                                  1,230         336 (27.3)
   Myocardial infarction                                                    1,222         96 (7.9)
   Stroke/transient ischemic attack                                         1,214         64 (5.3)
   Peripheral arterial disease                                              1,221         122 (10.0)

**Note:**

Overlap because of multiple comorbidities.

**Abbreviations:** HbA~1c~, glycosylated hemoglobin; SD, standard deviation.

###### 

Primary efficacy measures of HbA~1c~ and FPG

                                           Post-baseline   End of follow-up   Difference     95% CI
  ---------------------------------------- --------------- ------------------ -------------- --------------
  Mean HbA~1c~, % (n=1,210)                8.51 ±0.81      7.36±0.88          −1.15±0.91     −1.20; −1.10
   HbA~1c~ level \<6.5%, n (%) (n=1,262)   --              104 (8.2)          6.8%; 9.9%     
   HbA~1c~ level \<7.0%, n (%) (n=1,262)   --              397 (31.5)         28.9%; 34.1%   
  Mean FPG, mg/dL (n=1,197)                174±47          127±31             −47.3±44.1     −49.8; −44.8
   \<100 mg/dL n (%) (n=1,262)             --              150 (11.9)         10.2%; 13.8%   

**Abbreviations:** HbA~1c~, glycosylated hemoglobin; CI, confidence interval; FPG, fasting plasma glucose.

###### 

Secondary outcome measures

                                                                                  Post-baseline   End of follow-up   Difference     95% CI
  ------------------------------------------------------------------------------- --------------- ------------------ -------------- --------------
  Individual FPG treatment goals (n=1,208)                                                                                          
   \<100 mg/dL, n (%)                                                             --              61 (5.0)           --             3.9%; 6.4%
   100 to \<130 mg/dL, n (%)                                                      --              945 (78.2)         --             75.8%; 80.5%
   ≥130 mg/dL, n (%)                                                              --              202 (16.7)         --             14.7%; 18.9%
  Mean insulin dose per day (n=1,180)                                             13.43           20.39              +6.96±7.70     6.52; 7.40
  Insulin injection (n=1,262)                                                                                                       
   Once daily insulin injection, n (%)                                            1,219 (96.59)   1,140 (90.33)      --             --
   Administration time point                                                                                                        
    Morning, n (%)                                                                201 (15.93)     189 (14.98)        --             --
    Lunch, n (%)                                                                  17 (1.35)       12 (0.95)          --             --
    Evening, n (%)                                                                463 (36.69)     433 (34.31)        --             --
    Bedtime, n (%)                                                                538 (42.63)     506 (40.10)        --             --
    Twice daily, n (%)                                                            23 (1.82)       37 (2.93)          --             --
    No data, n (%)                                                                20 (1.58)       85 (6.74)          --             --
   Mean metformin dose, mg (n=1,241)                                              1,888.56        1,881.41           −7.15±145.19   −15.24; 0.94
   Mean body weight, kg (n=1,227)                                                 89.56± 16.8     88.58±16.3         −0.98±3.90     −1.19; −0.76
  Mean consumption of blood glucose test strips per month at 20 weeks (n=1,067)   41.59±37.53     45.06±36.30        +3.47±36.46    1.28; 5.66
  Mean consumption of pen needles per month at 20 weeks (n=1,183)                 --              24.58±14.75        --             23.74; 25.42

**Abbreviations:** CI, confidence interval; FPG, fasting plasma glucose.

###### 

Safety and rates of hypoglycemia

                             n available       AE rate, n (%)                         ADR rate, n (%)
  -------------------------- ----------------- -------------------------------------- -----------------------
  Any event                  1,483             13 (0.88) \[29 events\]                2 (0.13) \[5 events\]
   Hypoglycemia              1,483             3 (0.20)                               2 (0.13)
   Dizziness                 1,483             2 (0.13)                               0
   Erysipelas                1,483             2 (0.13)                               0
   Hyperhidrosis             1,483             2 (0.13)                               1 (0.07)
   Weight gain               1,483             2 (0.13)                               1 (0.07)
   Convulsion                1,483             0                                      1 (0.07)
  Serious events             1,483             6 (0.40)                               1 (0.07)
  Death                      1,483             1 (0.07)                               0
                                                                                      
                             **n available**   **Hypoglycemia, n (%) or mean ± SD**   
                                                                                      
  Confirmed hypoglycemia     1,243             29 (2.33)                              
   Mean number of episodes   1,238             1.88±1.03                              
  Nocturnal hypoglycemia     1,240             6 (0.48)                               
   Mean number of episodes   1,240             1.67±0.82                              
  Severe hypoglycemia        1,241             4 (0.32)                               
   Mean number of episodes   1,241             1.0±0.0                                

**Abbreviations:** AE, adverse event; ADR, adverse drug reaction; SD, standard deviation.
